Related Experiment Video
Updated: Jun 9, 2025

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
GLP1R Gene Expression and Kidney Disease Progression.
Jefferson L Triozzi1, Zhihong Yu2, Ayush Giri3,4
1Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Higher genetic expression of the glucagon-like peptide 1 receptor (GLP-1R) was linked to a reduced risk of kidney disease progression. This suggests GLP-1 receptor agonists may offer kidney protection beyond weight and glucose control.
Area of Science:
- Pharmacology and Nephrology
- Genetics and Precision Medicine
Background:
- Glucagon-like peptide 1 receptor agonists (GLP-1RAs) show potential for kidney protection.
- These benefits may extend beyond their established effects on weight and glycemic control.
Purpose of the Study:
- To investigate the association between genetically proxied GLP-1RAs and the progression of kidney disease.
- To explore potential nephroprotective mechanisms independent of metabolic factors.
Main Methods:
- A genetic association study using a national retrospective cohort from the US Department of Veterans Affairs Million Veteran Program (n=353,153).
- Calculated a genetic risk score for systemic GLP1R gene expression based on genetic variants.
- Assessed the primary composite outcome of incident end-stage kidney disease or a 40% decline in estimated glomerular filtration rate using Cox proportional hazards regression.
Main Results:
- Higher genetic GLP1R gene expression was associated with a lower risk of kidney disease progression (adjusted HR, 0.96; 95% CI, 0.92-1.00; P=.04).
- This association remained consistent in sensitivity analyses stratified by diabetes or obesity status.
- Approximately 4.6% of the cohort experienced kidney disease progression during a median follow-up of 5.1 years.
Conclusions:
- Increased GLP1R gene expression is linked to a modest reduction in kidney disease progression risk.
- Findings support pleiotropic nephroprotective effects of GLP-1RAs, independent of weight and glycemic control.
- Highlights the potential for genetic insights into drug mechanisms and therapeutic benefits.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
Cell Specific Gene Expression
Glomerular Filtration Rate and its Regulation
GFR regulation involves two primary intrinsic controls: the myogenic and tubuloglomerular feedback mechanisms.
The myogenic...

